Background: Papillary thyroid carcinoma (PTC), the most common type of thyroid malignancy, usually possesses mutations, either RET/PTC rearrangement or BRAF mutation. Both mutations can activate the mitogenactivated protein kinase kinase/extracellular signalrelated kinase signaling transduction pathway, which results in activation of transcription factors that regulate cellular proliferation, differentiation, and apoptosis.
P
APILLARY THYROID CARCINOmas (PTCs) are the most common type of thyroid malignancy. BRAF mutations account for only 8% of mutations in all human cancers, but the percentage is much higher in PTC. [1] [2] [3] [4] The incidence of BRAF mutations ranges from 29% to 83% depending on the cohort being studied. 1 The most common type of BRAF mutation in cancer is a T → A substitution at nucleotide 1799 that results in conversion of valine to glutamic acid at codon 600 (V600E) of the BRAF protein on exon 15. [2] [3] [4] The negative charge introduced by glutamic acid at position 600 mimics the effect of phosphorylation at an adjacent site when BRAF is activated and results in constitutive activation of BRAF. 3 The high rate of BRAF mutation in PTC makes PTC an ideal system for testing BRAF inhibitors. Other mutations commonly found in PTC are the RET/PTC rearrangements (11 different RET/PTC rearrangements have been reported; the RET/PTC1, RET/PTC2, and RET/PTC3 rearrangements have been studied most). 5, 6 The incidence of RET/PTC rearrangements in PTC ranges from 2.5% to 67.0% depending on the cohort being studied. The RET/PTC rearrangements result in constitutive activation of RET tyrosine kinase. Either mutation (RET/PTC rearrangement or BRAF mutation) can activate the mitogen-activated protein kinase kinase (MEK1/2 or MAPKK). The MEK1/2 then activates the MAPK (extracellular signal-related kinase 1/2 [ERK1/2]) signaling transduction pathway, resulting in activation of a variety of transcription factors that regulate cellular proliferation, differentiation, and apoptosis. [2] [3] [4] Several specific MEK1/2 inhibitors have been developed in the past few years. The first commercially available MEK1/2 inhibitors were PD98059 and U0126. We previously tested both inhibitors in PTC cells and found that both could inhibit PTC cell proliferation and decrease the phosphorylation of ERK1/2 (p-ERK1/2). 7 De-spite the effects of these inhibitors on PTC cells, PD98059 and U0126 were used for in vitro study only owing to the poor solubility of PD98059 and the inactivity of U0126 in vivo. 8 CI-1040 (PD184352) (Pfizer Global Research and Development, Ann Arbor, Michigan) is a small-molecule inhibitor with specific activity against MEK1/2. This orally active inhibitor has been tested in other cancers, including pancreatic, colon, breast, and non-small-cell lung cancers and was well tolerated by patients in phase 2 trials. 9 In this study, we tested the effects of CI-1040 in PTC cell lines that possessed either a BRAF mutation or an RET/ PTC1 rearrangement, both of which constitutively activate the BRAF-MEK1/2-ERK1/2 pathway. We found that CI-1040 inhibited PTC cell growth in vitro and in vivo at serologically achievable doses.
METHODS

CELL CULTURE
The PTC cell line carrying the RET/PTC1 rearrangement BHP2-7 (a subclone of TPC-1) was used in this study. 10, 11 The cells were maintained in RPMI1640 (Mediatech Inc, Herndon, Virginia) containing 10% fetal bovine serum (Hyclone, Logan, Utah), nonessential amino acid mixture (Cambrex BioScience, Walkers, Maryland), 1mM sodium pyruvate (Cambrex BioScience), and 2mM L-glutamine in a 37°C incubator supplied with 95% air and 5% carbon dioxide. A BRAF-mutated PTC cell line (K2) was maintained in Dulbecco Modified Eagle Medium: Nutrient Mixture F-12 (Mediatech Inc) containing 10% fetal bovine serum and 2mM L-glutamine.
REAGENTS
CI-1040 was dissolved in dimethyl sulfoxide (DMSO) as a 10mM stock solution and was stored at −20°C for in vitro study. For in vivo experiments, CI-1040 was dissolved in Cremophor EL-95% ethanol (50:50) (Sigma-Aldrich Corp, St Louis, Missouri) and was diluted with water before use.
CELL PROLIFERATION ASSAY
BHP2-7 and K2 cells (10 4 ) were plated in 24-well plates (Costar, Cambridge, Massachusetts) in triplicate for 4 days in a 37°C incubator. CI-1040 was added to the cells on day 0 or on days 0 and 2. For the MTT assay, 0.2 mL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) dissolved in 0.8% sodium chloride solution at 5 mg/mL was added to each well. After incubating the cells at 37°C for 3 hours, the liquid was aspirated from the wells and discarded. Stained cells were dissolved in 0.5 mL of DMSO, and their absorption at a wavelength of 570 nm (OD570) was ascertained using a multidetection microplate reader (Synergy HT; BioTek Instruments, Winooski, Vermont). For the concentration of CI-1040 needed to inhibit 50% cell growth (GI 50 ), the MTT assay was performed on day 3. For cell growth curves, the MTT assay was performed every day on days 0 to 4. Cell growth was calculated as 100 ϫ (T-T0)/(C-T0), where T is the OD570 reading after treating the cells with CI-1040 for 72 hours, T0 is the OD570 reading at day 0, and C is the OD570 reading of cells treated with DMSO only after 72 hours. The GI 50 was determined using Prism 3.0 (GraphPad Software, San Diego, California) based on the cell growth at each CI-1040 concentration.
CELL CYCLE ANALYSIS
BHP2-7 and K2 cells (2ϫ10 6 ) were plated the day before treatment in a 10-cm dish. On the day of treatment, CI-1040 was added to the cells for 24 hours at 37°C. Cells were treated with trypsin and collected, washed once in 0.8% sodium chloride solution, fixed in 5 mL of ethanol, and stored at 4°C overnight. Propidium iodide (50 µg/mL, 1 mL) containing DNasefree RNase (3.3 µg/mL) (Roche Applied Science, Indianapolis, Indiana) was added to the fixed cells, which were then incubated at 37°C for 30 minutes. Cell cycles were determined using a flow cytometer (FACSCalibur; BD Biosciences, San Jose, California).
WESTERN BLOT ANALYSIS
Protein extracts from PTC cells were prepared in lysis buffer containing 20mM Tris hydrochloride (pH 7.4), 1% Triton X-100, 300mM sodium chloride, 1mM phenylmethylsulfonyl fluoride, 50mM sodium fluoride, 1mM sodium vanadate, and 1ϫproteinase inhibitor cocktail III (Calbiochem, San Diego). Total protein concentrations were estimated using the Bradford assay (Bio-Rad, Hercules, California), with bovine serum albumin as a standard. For Western blot analysis, proteins were resolved on 10% or 4-to 20% gradient sodium dodecyl sulfatepolyacrylamide gels using an electrophoresis system (MiniProtean II; Bio-Rad). The proteins were then transferred to nitrocellulose membranes (Hybond ECL; GE Healthcare Bioscience, Piscataway, New Jersey) using a mini-transblot electrophoretic transfer cell (Bio-Rad) at 80 V for 1 hour at room temperature. After transfer, the membranes were blocked and probed with antibodies at 4°C overnight as indicated by the manufacturer. Antibodies for p-ERK1/2, total ERK1/2, poly (ADP-ribose) polymerase (PARP), caspase-9, caspase-3, and survivin (Cell Signaling Technology, Danvers, Massachusetts) were used at a dilution of 1:1000; a monoclonal antibody against actin (Sigma-Aldrich Corp) was used at a dilution of 1:3000. The cyclin D1 antibody (Santa Cruz Biotechnology Inc, Santa Cruz, California) was used at a dilution of 1:400 and was incubated with membrane for 2 hours at room temperature.
TUNEL ASSAY
The PTC cells were treated with 2µM CI-1040 for 3 or 4 days and were trypsinized to single cells. Cisplatin, 1 mg/mL (Teva Parenteral Medicines Inc, Irvine, California), was used as a positive control for apoptosis. The TUNEL (terminal deoxynucleotide transferase-mediated dUTP nick-end labeling) assay was performed using a fluorometric TUNEL system (DeadEnd; Promega Corp, Madison, Wisconsin) according to the manufacturer's protocol. Apoptotic cells were analyzed using a FACSCalibur flow cytometer.
TUMOR GROWTH IN ATHYMIC MICE USING AN ORTHOTOPIC MODEL
Athymic Ncr-nu/nu mice, aged 8 to 12 weeks, were obtained from the National Cancer Institute (Frederick, Maryland) and were housed for at least a week after arrival. All experimental procedures and care for mice were performed in accordance with the Institutional Animal Care and Use Committee and the Department of Veterinary Medicine at The University of Texas M. D. Anderson Cancer Center. The procedures for an orthotopic thyroid carcinoma model in mice have been described elsewhere. 12 The PTC cells (1ϫ10 tored daily for tumor growth. Two to 3 weeks after inoculation, mice were given 150 mg/kg of CI-1040 dissolved in Cremophor EL-95% ethanol (50:50) and diluted with water twice daily (300 mg/kg/d) by means of oral gavage for 5 consecutive days each week for 3 weeks. Tumor sizes were measured using calipers at the end of the 3 weeks (ex vivo after harvesting the tissue), and tumor volume (V) was calculated using the following formula: (V=[length ϫ width 2 ]/2). Control mice were given diluted Cremophor EL-95% ethanol (50:50) only.
STATISTICAL ANALYSIS
Statistical analysis was performed using the unpaired t test. PՅ.05 was considered to be statistically significant.
RESULTS
GI 50 OF CI-1040 IN PTC CELLS
To monitor the effects of CI-1040 on inhibition of PTC cell growth, the GI 50 was determined in PTC cells. Serial dilution (1:5) of CI-1040 was prepared, starting at 20µM to 3.2nM. After 3 days of incubation with varying concentrations of CI-1040, MTT assays were performed and cell growth was calculated. The GI 50 for PTC cells with a BRAF mutation was 0.052µM; the GI 50 for PTC cells with the RET/PTC1 rearrangement was 1.1µM (data not shown).
INHIBITION OF CELL GROWTH BY CI-1040
After the GI 50 of CI-1040 in PTC cells was determined, PTC cells were divided into 3 groups, and each group was treated with a different concentration of CI-1040: approximately the GI 50 (0.05µM for PTC cells with a BRAF mutation and 1µM for PTC cells with the RET/PTC1 rearrangement), 10-fold lower than the GI 50 (0.005µM for PTC cells with a BRAF mutation and 0.1µM for PTC cells with the RET/PTC1 rearrangement), or 10-fold higher than the GI 50 (0.5µM for PTC cells with a BRAF mutation and 10µM for PTC cells with the RET/PTC1 rearrangement). Using MTT assays, after 4 days of treatment with CI-1040, PTC cells with a BRAF mutation showed 90% growth inhibition at a 0.5µM dose, 59% inhibition at 0.05µM, and 27% inhibition at 0.005µM compared with cells treated with DMSO only (PϽ.001 for all) (Figure 1) . In PTC cells with the RET/PTC1 rearrangement, CI-1040 inhibited 86% of cell growth at 10µM (P = .001), 51% at 1µM (P Ͻ .001), and 11% at 0.1µM (P = .03) compared with cells treated with DMSO only (Figure 1 ). During 4-day treatment with CI-1040, growth was inhibited in the same percentage of PTC cells regardless of whether CI-1040 was added once (on day 0) or twice (on days 0 and 2) (data not shown). These results suggest that CI-1040 is a stable inhibitor that can inhibit the growth of PTC cells and that PTC cells bearing a BRAF mutation are significantly more sensitive to CI-1040 than their RET/ PTC1 counterparts.
To determine the mechanism of cell growth inhibition in PTC cells after CI-1040 treatment, cell cycle analysis was performed after the PTC cells were treated with 1µM CI-1040 for 24 hours (Figure 2) . More than 88% of PTC cells carrying the RET/PTC1 rearrangement were in G1 arrest, whereas 57% of untreated PTC cells were in the G1 phase. After CI-1040 treatment, only 5% of PTC cells were in the G2/M and S phases, whereas 23% of untreated cells were in the G2/M phase and 19% were in the S phase. Similar results were observed in PTC cells with a BRAF mutation. More than 85% of PTC cells with a BRAF mutation were in G1 arrest compared with untreated cells (61% in G1 phase). After CI-1040 treatment, only 7% of PTC cells with a BRAF mutation were in the G2/M phase and 6% were in the S phase, whereas 15% of untreated cells were in the G2/M phase and 23% were in the S phase. No significant change in the apoptotic phase was observed in either type of PTC cells after CI-1040 treatment for 24 hours (Figure 2 ).
DEPHOSPHORYLATION OF ERK1/2 IN PTC CELLS BY CI-1040
CI-1040 is a specific MEK1/2 inhibitor, and the downstream effectors of these kinases are ERK1/2. The ability of CI-1040 to decrease p-ERK1/2 was examined. The PTC cells were treated with different concentrations of CI-1040 for 1 hour, and the p-ERK1/2 was reduced at 0.1µM and was completely abolished at 1µM for PTC cells with a BRAF mutation (Figure 3A) or the RET/PTC1 rearrangement ( Figure 3B ). The duration of the dephosphorylation of ERK1/2 in PTC cells with a BRAF mutation lasted up to 96 hours ( Figure 3A ). For cells with the RET/PTC1 rearrangement, p-ERK1/2 became detectable as early as 6 hours after treatment with CI-1040, and p-ERK1/2 returned to its pretreatment level after 72 hours ( Figure 3B ). TheabilityofCI-1040todecreasetheexpressionofp-ERK1/2 was observed to be the same whether CI-1040 was added to PTC cells once (at day 0) or twice (at days 0 and 2) during the 96-and 72-hour treatments (data not shown). Total ERK1/2 expression remained the same during all treatments. These data suggest that the downstream effects of CI-1040 treatment could effectively result in the dephosphorylation of ERK1/2. The dephosphorylation effect lasted longer in PTC cells with a BRAF mutation than in those with the RET/ PTC1 rearrangement.
CASPASES AND PARP CLEAVAGES DETECTED IN PTC CELLS WITH A BRAF MUTATION AFTER CI-1040 TREATMENT
Survivin and XIAP are antiapoptotic proteins. The expression of these proteins decreases in cells that undergo apoptosis. 13, 14 The PTC cells were treated with 1µM CI-1040, and the expression of both proteins was analyzed using Western blotting. In PTC cells with either a BRAF mutation or the RET/PTC1 rearrangement, the expression of survivin was lost after treating the cells with CI-1040 for 16 hours (data not shown) and did not recover during observations extending up to 72 hours. No change in the expression of XIAP was observed in PTC cells treated with 1µM CI-1040 for up to 4 days (data not shown).
To further investigate the mechanism of cell growth inhibition in PTC cells with a BRAF mutation by CI-1040, we evaluated expression of the caspase-9, caspase-3, and caspase-3 substrate PARP as indicators of apoptosis using Western blot analysis. The PTC cells with a BRAF mutation showed cleaved caspase-9 after 1 day of treatment with CI-1040, cleaved caspase-3 after 2 days of treat- In addition to the observed PARP cleavage on Western blots, the effects of CI-1040 on PTC cells were further tested using the TUNEL assay. In BRAF-mutated PTC cells, 11% and 24% of cells were apoptotic after treating with CI-1040 for 3 and 4 days, respectively ( Figure 4B ). In RET/PTC1-rearranged PTC cells, less than 1% of cells were apoptotic after treating with CI-1040 for up to 4 days. These data confirm the results observed on Western blots that BRAF-mutated PTC cells undergo apoptosis after CI-1040 treatment, whereas PTC cells with the RET/PTC1 rearrangement do not.
INHIBITION OF TUMOR GROWTH BY CI-1040 IN AN ORTHOTOPIC MOUSE MODEL
The inhibitory effects of CI-1040 were tested in vivo using an orthotopic mouse model. The PTC cells were inoculated in situ into the mouse thyroid. After 2 to 3 weeks, CI-1040 was given to these mice (see the "Methods" section) for 3 weeks. At the end of the 3 weeks, tumor sizes were measured and tumor volume was calculated (Table) . After CI-1040 treatment, the mean tumor volume was smaller in mice with tumor from PTC cells carrying a BRAF mutation than in untreated (vehicle) mice (204.2 mm 3 compared with 297.3 mm 3 , 31.3% reduction, PϽ.001). The mean tumor volume was also smaller in mice with tumor from PTC cells carrying the RET/PTC1 rearrangement than in untreated (vehicle) mice (368.5 mm 3 compared with 701.9 mm 3 , 47.5% reduction, P = .004). No toxic effects were observed in any mice when they were treated with CI-1040. These data suggest that CI-1040 inhibits tumor growth in vivo in PTC cells having either the RET/PTC1 rearrangement or a BRAF mutation.
COMMENT
We examined the effects of the MEK1/2 inhibitor CI-1040 in PTC cells. We found that CI-1040 effectively inhibited PTC cell growth in vitro and in vivo. Previous studies 15 have demonstrated that CI-1040 is a specific inhibitor of MEK1/2. After CI-1040 treatment in a colon cancer cell line, only the expression of p-ERK1/2 was affected, and no change in the expression of p-JNK, pP38, and pAKT was detected by means of Western blot analysis. 15 In the present study, PTC cells with a BRAF mutation were sensitive to CI-1040 treatment in vitro, as the GI 50 in these cells is only 0.052µM, which is in close agreement with the half-maximal inhibitory concentration of CI-1040 to the enzymatic activity of pure MEK1 at 0.017µM. In contrast, at 1.1µM, the GI 50 of PTC cells with the RET/PTC1 rearrangement was much higher.
At the molecular level, the expression of p-ERK1/2 was suppressed in both types of PTC cells after treatment with 1µM CI-1040 for 1 hour. The rapid dephosphorylation of ERK1/2 has been reported in other types of cancer, including the breast cancer cell line MDA-MB-231, 16 malignant schwannoma cell lines, 17 and colon cancer cell lines. 15 The duration of the dephosphorylation of ERK1/2 by CI-1040 was different in different types of PTC cells. Dephosphorylation of ERK1/2 by CI-1040 lasted longer in PTC cells with a BRAF mutation (Ͼ96 hours) than in PTC cells with the RET/PTC1 rearrangement (approximately 6 hours). The regulation of p-ERK1/2 in these cells could explain this difference. In PTC cells with a BRAF mutation, the only known substrates of BRAF are MEK1/2, which activate ERK1/2. However, in PTC cells with the RET/PTC1 rearrangement, the resulting constitutive activated RET kinase is regulated by other signal transduction pathways (JNK, PI3K, or PLC␥) in addition to the RAF-MEK1/2-ERK1/2 pathway. 6 Studies have shown that the expression of p-MEK1/2 is higher in PTC cells with a BRAF mutation than in PTC cells with the RET/PTC1 rearrangement. 18 Thus, the ability of CI-1040 to dephosphorylate ERK1/2 in the presence of the BRAF mutation is a strong and dramatic one.
We also observed that CI-1040 was a stable in vitro inhibitor of PTC cell proliferation and suppressed p-ERK1/2 expression in PTC cells. After the dephosphorylation of ERK1/2, both types of PTC cells showed suppression of survivin 16 hours after CI-1040 treatment and G1 arrest at 24 hours. The reduction in survivin expression and G1 arrest have been observed in other types of cancer cells, including colon cancer cells, 15 ovarian cancer cells, 19 and malignant schwannoma cells. 17 Other researchers 19 have reported that G1 arrest induced by CI-1040 is only observed in cells with a BRAF mutation or a KRAS mutation and is not seen in cells carrying the wild-type BRAF. In the present study, we observed G1 arrest in PTC cells with the RET/PTC1 rearrangement (with wild-type BRAF) and in those with a BRAF mutation. The events after G1 arrest seemed to be different in PTC cells with a BRAF mutation than in those with the RET/PTC1 rearrangement. As indicated by the detection of cleaved caspase-9, caspase-3, and cleaved PARP (3 or 4 days) and by TUNEL assay (3 or 4 days), CI-1040 induced apoptosis in PTC cells with a BRAF mutation after 24 hours of treatment. In PTC cells with the RET/PTC1 rearrangement, cytostasis was observed, activation of the caspase system was not detected, and no apoptotic cells were detected in TUNEL assay after up to 4 days of CI-1040 treatment. Because there are no available PTC cell lines carrying the RET/PTC2 and RET/PTC3 rearrangements, the effect of CI-1040 on these rearrangements was not tested. Although the mechanisms of the different responses to CI-1040 treatment by different types of PTC cells are unclear, we ruled out the involvement of p53 due to its mutation status in PTC cells. This p53-independent apoptosis induced by CI-1040 has been reported in malignant schwannoma cells by Mattingly et al, 17 who showed that CI-1040 induced apoptosis in 3 different cell lines, 1 with a wild-type p53, another with a mutant p53, and the third with no p53 (p53 null).
CI-1040 was previously tested in a phase 2 trial in patients with advanced non-small-cell lung, breast, colon, or pancreatic cancer. 9 No antitumor effect by CI-1040 was observed in these patients. A BRAF mutation was reported in 12% of patients with colon cancer 1, 20 and in less than 10% of patients with breast cancer 21 ; no BRAF mutation was reported in patients with pancreatic cancer. 
